194 related articles for article (PubMed ID: 16484713)
21. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
22. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
[TBL] [Abstract][Full Text] [Related]
25. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
Bernier-Chastagner V; Grill J; Doz F; Bracard S; Gentet JC; Marie-Cardine A; Luporsi E; Margueritte G; Lejars O; Laithier V; Mechinaud F; Millot F; Kalifa C; Chastagner P
Cancer; 2005 Dec; 104(12):2792-7. PubMed ID: 16265674
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
Tsuda H; Iemura A; Sata M; Uchida M; Yamana K; Hara H
Kurume Med J; 1996; 43(2):137-47. PubMed ID: 8755117
[TBL] [Abstract][Full Text] [Related]
29. The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.
Sugita Y; Tsuda H; Maruiwa H; Hirohata M; Shigemori M; Hara H
Kurume Med J; 1995; 42(3):133-40. PubMed ID: 7474850
[TBL] [Abstract][Full Text] [Related]
30. Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Ohno M; Natsume A; Fujii M; Ito M; Wakabayashi T
Pediatr Blood Cancer; 2009 Jul; 53(1):37-41. PubMed ID: 19260101
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
MacDonald TJ; Arenson EB; Ater J; Sposto R; Bevan HE; Bruner J; Deutsch M; Kurczynski E; Luerssen T; McGuire-Cullen P; O'Brien R; Shah N; Steinbok P; Strain J; Thomson J; Holmes E; Vezina G; Yates A; Phillips P; Packer R
Cancer; 2005 Dec; 104(12):2862-71. PubMed ID: 16315242
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases.
Yoshimura J; Onda K; Tanaka R; Takahashi H
Neurol Med Chir (Tokyo); 2003 Aug; 43(8):375-82; discussion 382. PubMed ID: 12968803
[TBL] [Abstract][Full Text] [Related]
35. Population-based Study Determining Predictors of Cancer-Specific Mortality and Survival in Pediatric High-grade Brainstem Glioma.
Maxwell R; Luksik AS; Garzon-Muvdi T; Yang W; Huang J; Bettegowda C; Jallo GI; Terezakis SA; Groves ML
World Neurosurg; 2018 Nov; 119():e1006-e1015. PubMed ID: 30138731
[TBL] [Abstract][Full Text] [Related]
36. Cervicomedullary tumors in children.
McAbee JH; Modica J; Thompson CJ; Broniscer A; Orr B; Choudhri AF; Boop FA; Klimo P
J Neurosurg Pediatr; 2015 Oct; 16(4):357-66. PubMed ID: 26114990
[TBL] [Abstract][Full Text] [Related]
37. The preventive effect of antineoplaston AS2-1 on HCC recurrence.
Tsuda H; Sata M; Kumabe T; Uchida M; Hara H
Oncol Rep; 2003; 10(2):391-7. PubMed ID: 12579278
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
[TBL] [Abstract][Full Text] [Related]
39. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
40. Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas.
Klimo P; Nesvick CL; Broniscer A; Orr BA; Choudhri AF
J Neurosurg Pediatr; 2016 Jan; 17(1):57-65. PubMed ID: 26474099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
